GlassScriptPhysician profile
Saira Naseer
NPI 1487650503
$643.39
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $111 · 2021: $47.66 · 2022: $32.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $87.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.10 | 2019 | |
| Pfizer INC. | $66.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.70 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.82 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.15 | 2019 | |
| Amgen INC. | $20.93 | 2019 | |
| Astellas Pharma US INC | $18.75 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.10 | 2019 | |
| Allergan, INC. | $17.92 | 2020 | |
| Medtronic, INC. | $16.50 | 2022 | |
| Lilly USA, LLC | $14.06 | 2019 | |
| Merck Sharp & Dohme LLC | $12.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Naseer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.